JPMorgan Upgrades Sanofi-Aventis (SNY) to Neutral

JPMorgan upgraded Sanofi-Aventis (NYSE: SNY) from Underweight to Neutral.

Analyst Richard Vosser sees roughly 3 percent upside to the stock and tells clients he does not believe the stock warrants a significant discount to sector. He says the pressure to diabetes business appears to be reflected in the consensus estimates, he forecasts business EPS CAGR of 7 percent from 2017 to 2020 and notes his teams EPS forecasts for EPS are somewhere between 1 and 4 percent above the consensus. Finally, he notes that Dupixent launch may likely be slower than expected according to morning research note.

For an analyst ratings summary and ratings history on Sanofi-Aventis click here. For more ratings news on Sanofi-Aventis click here.

Shares of Sanofi-Aventis closed at $44.58 yesterday.

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Cummins (CMI) PT Lowered to $675 at Jefferies
• Benchmark Reiterates Buy Rating on Rank One Computing (ROC)